Brief: Veracyte Q1 Revenue USD 96.8 Million Vs. IBES Estimate USD 93.4 Million
07/05/2024 21:05
May 07 (Reuters) - Veracyte Q1 adjusted operating expenses USD 67.1 million. * Q1 net income USD -1.9 million * Q1 gross margin 65% * outlook FY revenue USD 402-410 million * outlook FY revenue growth 11-14%
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina